Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
SAN FRANCISCO, Nov. 4, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced the presentation of additional clinical data from the Phase 1b study evaluating multiple ascending doses of NKTR
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress
06:00pm, Thursday, 29'th Oct 2020
SAN FRANCISCO, Oct. 29, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call at ACR 2020 with company management and Dr.
Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets
06:00pm, Wednesday, 28'th Oct 2020
SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2020 on Thursday, November 5, 2020, after the close of U.S.-ba
DAVENPORT & Co LLC Sells 4,250 Shares of Nektar Therapeutics (NASDAQ:NKTR)
06:10am, Monday, 19'th Oct 2020
DAVENPORT & Co LLC decreased its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 6.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 58,300 sh
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by BidaskClub
01:12am, Saturday, 10'th Oct 2020
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Saturday, BidAskClub reports.
Charles Schwab Investment Management Inc. Raises Stake in Nektar Therapeutics (NASDAQ:NKTR)
08:58am, Monday, 28'th Sep 2020
Charles Schwab Investment Management Inc. boosted its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 11.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The
Engineers Gate Manager LP Sells 24,690 Shares of Nektar Therapeutics (NASDAQ:NKTR)
06:52am, Sunday, 27'th Sep 2020
Engineers Gate Manager LP reduced its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 63.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchang
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Director Sells $44,415.00 in Stock
08:36am, Friday, 25'th Sep 2020
Nektar Therapeutics (NASDAQ:NKTR) Director Jeffrey Robert Ajer sold 2,250 shares of the stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $19.74, for a t
Nektar Therapeutics (NASDAQ:NKTR) CFO Sells $39,920.00 in Stock
08:36am, Friday, 25'th Sep 2020
Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 2,000 shares of the firm’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $19.96, fo
Nektar Therapeutics (NASDAQ:NKTR) Shares Purchased by Canada Pension Plan Investment Board
06:48am, Tuesday, 22'nd Sep 2020
Canada Pension Plan Investment Board boosted its position in Nektar Therapeutics (NASDAQ:NKTR) by 1,184.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The
Nektar Looks Undervalued, But The Biggest Value-Driving Events Are Still In 2021
04:00pm, Friday, 28'th Aug 2020
Nektar is largely marking time ahead of some medium impact trial updates in November and game-changing updates in 2021 for the melanoma and bladder cancer programs.
Gil M. Labrucherie Sells 6,245 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
08:12am, Saturday, 22'nd Aug 2020
Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 6,245 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $19.67, for
Did Hedge Funds Make The Right Call On Nektar Therapeutics (NKTR) ?
01:42pm, Wednesday, 12'th Aug 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market
Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR) today announced that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nekt
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress
03:35pm, Friday, 07'th Aug 2020
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
